Cypherpunk Technologies Inc. 2025 Annual Report: Key Takeaways for Investors

Cypherpunk Technologies Inc. (Nasdaq: CYPH) has released its Annual Report for the fiscal year ended December 31, 2025, marking a transformative period for the company. Formerly known as Leap Therapeutics, Inc., Cypherpunk completed a name change and corporate restructuring in late 2025, establishing a new wholly owned subsidiary, Leap Therapeutics, Inc., to continue its biotechnology operations. This article summarizes key developments from the report, with a focus on price-sensitive information for shareholders.

Corporate Transformation and Strategic Focus

• Corporate Name Change and Restructuring: On November 12, 2025, Cypherpunk filed a Charter Amendment, changing its name from Leap Therapeutics to Cypherpunk Technologies Inc. This move reflects a new strategic focus on privacy technology and digital asset treasury management, alongside ongoing biotechnology operations.
• Subsidiary Structure: The formation of Leap Therapeutics, Inc. as a subsidiary ensures continuity in biotech operations while allowing Cypherpunk to pursue its new mission in privacy technologies and digital assets.

Business Overview: Dual Focus on Privacy Technology & Biotechnology

• Privacy Technology Focus: Cypherpunk aims to become the first publicly traded company dedicated primarily to privacy technology. The company’s mission is to advance privacy infrastructure, leveraging disciplined capital allocation and investments in privacy-preserving digital assets.
• Digital Asset Treasury Strategy: Cypherpunk’s treasury strategy centers on acquiring Zcash (ZEC), a privacy-focused cryptocurrency, using proceeds from equity offerings and other capital raising activities. The company seeks to accumulate a meaningful share of ZEC’s circulating supply, but notes this objective may shift depending on market conditions and capital availability.
• Biotechnology Operations: Through its Leap Therapeutics subsidiary, Cypherpunk continues development of sirexatamab (DKN-01) and other oncology programs. The subsidiary maintains partnerships and licensing deals, including with Adimab, Inc., and is exploring commercialization and distribution strategies as its lead candidates move through clinical trials.

Competition & Market Position

• Privacy Technology and Digital Asset Competition: Cypherpunk is competing for capital with Exchange Traded Products (e.g., Grayscale Zcash Trust), larger digital assets like bitcoin, and other digital asset treasury companies (e.g., Strategy Inc.). The company positions itself as a leader in privacy tech, targeting a structural increase in global demand for privacy solutions.
• Biotechnology Competition: Leap Therapeutics faces competition from other oncology biotech firms and must navigate production, quality assurance, and regulatory hurdles. The company is considering building its own sales and marketing infrastructure or partnering for distribution once FDA approval is obtained.

Regulatory Environment & Risks

• Digital Assets: Multiple U.S. federal and state agencies, as well as foreign regulators, are scrutinizing digital asset markets. Issues include anti-money laundering, sanction evasion, and regulation of trading platforms. Congressional action, including the Digital Asset Market Clarity Act of 2025, could materially impact Cypherpunk’s operations and asset values.
• Biotechnology: Leap Therapeutics must obtain and maintain patent protection, navigate FDA approval processes, and ensure compliance with evolving regulatory standards. Changes in labeling or manufacturing post-approval could affect marketability and profitability.

Financial Highlights & Shareholder Information

• Public Float: As of June 30, 2025, the aggregate market value of voting and non-voting common stock held by non-affiliates was approximately \$12.1 million.
• Shares Outstanding: As of March 11, 2026, Cypherpunk reported 89,979,619 shares of common stock outstanding, par value \$0.001 per share.
• Nasdaq Listing: Cypherpunk’s common stock continues to trade on the Nasdaq Capital Market under the ticker CYPH.

Forward-Looking Statements & Key Risks

• Cypherpunk’s forward-looking statements include expectations around product development, clinical trial data, regulatory submissions, digital asset acquisitions, and strategic positioning. These are subject to risks including volatility in digital asset prices, correlation between digital asset values and the company’s stock, increased competition, regulatory changes, macroeconomic factors like inflation and interest rates, and the ability to maintain Nasdaq listing requirements.
• The company warns that actual results may differ materially from these statements, and shareholders should closely monitor regulatory developments, market conditions, and company disclosures.

Potential Price-Sensitive Information

• Strategic Pivot: The transition to a privacy tech and digital asset treasury company, alongside continued biotech operations, is a major shift that could impact valuation, investor base, and stock performance.
• Digital Asset Exposure: The company’s stock price may become more correlated with Zcash and other digital assets, increasing volatility and sensitivity to crypto market movements.
• Regulatory Risk: Pending U.S. and international regulation of digital assets could materially affect operations, asset values, and share price.
• Clinical & Commercial Progress: Success or failure in clinical trials, FDA approvals, and commercialization of biotech products could significantly move the share price.

Conclusion

Cypherpunk Technologies Inc. is undergoing a fundamental strategic transformation, positioning itself as a unique player in both privacy technology and biotechnology. Investors should be aware of the risks and opportunities associated with the dual focus, especially the exposure to digital asset volatility and regulatory uncertainty. The company’s progress in clinical trials, digital asset acquisitions, and regulatory compliance will be key drivers of future share performance. Shareholders are encouraged to follow company updates closely, as further developments could have material impacts on share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are based on current information and subject to risks and uncertainties. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions related to Cypherpunk Technologies Inc.

View CYPHERPUNK TECHNOLOGIES INC. Historical chart here